Effect of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, on measurement of serum 1,5‐anhydroglucitol (坎格列净,一种钠‐葡萄糖共转运体2抑制剂,对血清1,5‐脱水葡萄糖醇测定的影响)

@article{Balis2014EffectOC,
  title={Effect of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, on measurement of serum 1,5‐anhydroglucitol (坎格列净,一种钠‐葡萄糖共转运体2抑制剂,对血清1,5‐脱水葡萄糖醇测定的影响)},
  author={Dainius A. Balis and Cindy Tong and Gary E Meininger},
  journal={Journal of Diabetes},
  year={2014},
  volume={6}
}
Serum levels of 1,5-anhydroglucitol (1,5-AG) can be used as a measure of glycemic control in patients with diabetes. 1,5-anhydroglucitol is a non-metabolizable glucose analog that competes with glucose for renal reabsorption. In individuals with hyperglycemia, excess plasma glucose that enters the urine prevents renal reabsorption of 1,5-AG, leading to decreased serum 1,5-AG levels. Serum levels of 1,5-AG are determined using an enzymatic assay (GlycoMark; GlycoMark Inc., New York, NY, USA… Expand
Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol.
TLDR
CT negates the usual premise of AG measurement (that AG should increase with improved glycemic control), however, according to model calculations, a substantial and likely rapid effect of CT on [AG] means that AG measurement might provide an early marker for CT activity. Expand
1,5-anhydroglucitol in diabetes: its role in diagnostics, screening, glycemic status assessment, and the prediction of complications
TLDR
It has been proposed to combine 1,5-AG with assessment of fasting glucose for the screening purposes and the relatively high cost and lack of standardization restrain the use of 1,4-anhydroglucitol in clinical practice. Expand
Diabetes Screening: Detection and Application of Saliva 1,5-anhydroglucitol by Liquid Chromatography-mass Spectrometry.
TLDR
Saliva 1,5-AG combined with FPG or HbA1c improved the efficiency of diabetes screening and is robust in nonfasting measurements and a noninvasive and convenient tool for diabetes screening. Expand
Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
TLDR
Insight is provided into the mode of action, pharmacology, potential drug–drug interactions, clinical benefits, and safety considerations associated with use of the SGLT2 inhibitor canagliflozin in patients with T2DM and to provide information to enhance clinical pharmacists' understanding of canag liflozin. Expand
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
TLDR
Sex differences, baseline haemoglobin A1c (HbA1c) and serum uric acid (UA) levels, and log10‐transformed urinary N‐acetyl‐β‐D‐glucosaminidase ratio were significantly correlated with the reduction in serum UA levels at both 4 and 24 weeks in multivariate analysis. Expand
Review of Methods for Detecting Glycemic Disorders.
TLDR
Of the approaches considered, the 1-h PG has considerable potential as a biomarker for detecting glucose disorders if confirmed by additional data including health economic analysis, and whether the1-h OGTT is superior to genetics and omics in providing greater precision for individualized treatment requires further investigation. Expand
Sodium glucose cotransporter 2 inhibitors.
  • J. White
  • Medicine
  • The Medical clinics of North America
  • 2015
SGLT2 inhibition offers a novel mechanism to mitigate hyperglycemia in patients with diabetes and the introduction of SGLT2 has added a significant new tool to the antihyperglycemic armamentarium. AtExpand
SGLT 2 Inhibitors: A New Therapeutic Target And Its Role In Current Clinical Practice
TLDR
SGLT-2 inhibitors are new group of drugs recently approved by FDA to treat Diabetes, and mechanism of action, various adverse effects and the clinical role of various SGLt-2Inhibitors are discussed. Expand
Applications and pitfalls of hemoglobin A1C and alternative methods of glycemic monitoring.
TLDR
The main limitations for all alternative methods of glycemic monitoring are a lack of standardization for clinically useful cut-offs or guidelines, and a Lack of long-term data on their association with complications, particularly in varied patient populations. Expand
Emerging Diabetic Novel Biomarkers of the 21st Century
Diabetes is a growing epidemic with estimated prevalence of infected to reach ~592 million by the year 2035. An effective way to approach is to detect the disease at a very early stage to reduce theExpand
...
1
2
...

References

SHOWING 1-10 OF 14 REFERENCES
Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker.
TLDR
1,5-Anhydroglucitol, the 1-deoxy form of glucose, has been measured and used clinically in Japan for over a decade to monitor short-term glycemic control and may be a valuable complement to frequent self-monitoring or continuous monitoring of plasma glucose to confirm stable gly glucose control. Expand
Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay.
TLDR
It is concluded that 1,5AG responds sensitively and rapidly to changes in glycemia and monitors glycemic control in accordance with established markers. Expand
Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.
TLDR
These oral antidiabetic agents have the potential to improve glycemic control while avoiding hypoglycemia, to correct the glucotoxicity, and to promote weight loss. Expand
Efficacy and Safety of Canagliflozin Treatment in Older Subjects With Type 2 Diabetes Mellitus: A Randomized Trial
TLDR
Canagliflozin improved glycemic control, reduced body weight and systolic BP, and was generally well tolerated in older subjects with T2DM who were on background therapy with a variety of blood glucose–lowering agents. Expand
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
TLDR
Findings support the use of canagliflozin as a viable treatment option for patients who do not achieve sufficient glycaemic control with metformin therapy, and provide greater HbA1c reduction than does glimepiride, and is well tolerated in patients with type 2 diabetes receiving meetformin. Expand
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
TLDR
This study evaluated the efficacy and safety of canagliflozin in subjects with T2DM and stage 3 chronic kidney disease. Expand
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
TLDR
Canagliflozin improved glycaemia and reduced body weight vs placebo ( week 26) and sitagliptin (week 52) and was generally well tolerated in patients with type 2 diabetes on metformin. Expand
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
TLDR
This randomised, double‐blind, placebo‐controlled, Phase 3 study evaluated the efficacy and safety of canagliflozin as an add‐on to metformin plus sulphonylurea in patients with T2DM. Expand
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
TLDR
The efficacy and safety of canagliflozin were evaluated in subjects with T2DM inadequately controlled with diet and exercise. Expand
Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes
Aims  To compare the metabolic effects of pioglitazone, metformin, and glimepiride in the treatment of Japanese patients with newly diagnosed Type 2 diabetes.
...
1
2
...